



Do Good.

Investment Update

## Deal 1:

# Wanbury Limited

### | Borrower Profile

Wanbury Limited was incorporated in 1991 and is engaged in manufacturing and marketing of active pharmaceutical ingredient ("APIs") and formulations. It is the largest Indian exporter for Metformin and second largest exporter for Sertraline.

Metformin is the first line of treatment for diabetes and Sertraline is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. Majority of the revenue for Wanbury comes from export of these two APIs.

It has two FDA approved operational plants located in Patalganga near Mumbai and in Tanaku Andhra Pradesh.

### | Recent Updates

- During the quarter, company raised INR 60Cr from a leading NBFC at cost of 12.5% p.a. for refinancing existing financiers and for Capex. This marks Company's entry into regular banking for raising funds.
- Due to sharing of charge with the NBFC, Company has agreed to pay additional interest of 1.5% P.A payable monthly
- This investment from NBFC shall help company to save on interest cost by 5% p.a. and improve margins and ease out pressure on supply chain of the company.
- During the quarter US FDA inspection was conducted for Patalganaga plant without any adverse observations
- For the quarter ended on Jun'24 company reported Revenue and EBIDTA of INR 131CRs and 11CRs. This was low on account of capex undertaken at both the plants in view of upcoming US FDA visit.

### | Investment Summary

#### Instrument

**Unlisted Non-Convertible Debentures**

#### IRR

#### Date of Investment

**21 July 2023**

#### Tenure

**4 years**

#### Collateral Description

**First pari passu charge over entire fixed and current assets of the company and part pledge over stake held by promoters.**

#### Collateral Cover

**2.95 times**

## | Disclaimer

This document is intended only for the personal use of the prospective investors/contributors (herein after referred to as the Clients) to whom it is addressed or delivered and must not be reproduced or redistributed in any form to any other person without any prior written consent of Neo Wealth Management (NWM). The document does not purport to be all-inclusive, nor does it contain exhaustive information which a prospective investor may desire for its decision making. The document is neither approved, certified nor its contents is verified by SEBI.

The contents of this document are provisional and may be subject to change at the discretion of NWM. NWM reserves the right (but is not required) to correct any errors or omissions on the document. In the preparation of the material contained in this website/email/document, NWM has used information, calculation, cashflows that is publicly available, certain research reports including information developed in-house applying valid assumptions. NWM warrants that the contents of this document are true to the best of its knowledge, however, assume no liability for the relevance, accuracy, or completeness of the contents herein.

For the entire terms and conditions, please refer to: <https://www.neo-group.in/>

For any queries, please contact:

### **Do Good.**

903, B-Wing, 9th Floor, Marathon FutureX, Mafatlal Mills Compound, N.M. Joshi Marg,  
Lower Parel Mumbai 400013 IN